drugset / Trial / NCT00319189

Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients

NCT00319189

Phase 4 Completed 15 enrolled University of Oslo School of Pharmacy
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of the present study is to evaluate both the efficacy and safet of nateglinide in renal transplanta recipients with posttransplant diabetes mellitus or impaired glucose tolerance. Primarily will the change in glucose tolerance and acute insuline responce be addressed.

Timeline

Start
2002-11
Primary completion
Completion
2003-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Nateglinide Small molecule